AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 21 - (NewsRx.com & NewsRx.net) --
by Michelle Marble, staff medical writer -- Researchers in China have developed a malaria vaccine candidate appropriate for clinical trials.
"We constructed a live recombinant vaccinia virus vaccine candidate containing a synthesized hybrid gene termed 'HGFSP' encoding circumsporozoite protein (CSP), major merozoite surface antigen-1 (MSA1), major merozoite surface antigen-2 (MSA2), and ring-infected erythrocyte surface antigen (RESA) of Plasmodium falciparum, interleukin-1 (IL-1) and tetanus toxin (TT) epitopes," wrote Wenqi Dong and colleagues from the First Military Medical University. "Anti-recombinant vaccinia virus rabbit sera and immunoglobulin G (IgG) were tested in inhibition experiments in vitro."
Dong et al. published their study in the International Journal for Parasitology ("Assessment of a vaccinia virus vectored multi-epitope live vaccine candidate for Plasmodium falciparum," Int J Parasitol, January 2001;31(1):57-62).
The researchers observed that the recombinant vaccinia virus was capable of inhibiting the growth of P. falciparum in vitro. Next they evaluated the vaccine in vivo. Rabbits, rats, and mice were immunized with the recombinant virus. The ...
Source: HighBeam Research, Recombinant Vaccinia Virus Vaccine Stimulates Protective Immune...